LXRX

Lexicon PharmaceuticalsNasdaqGS:LXRX Stock Report

Market Cap

US$702.1m

7D

4.3%

1Y

200.0%

Updated

18 Sep, 2021

Data

Company Financials +
LXRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance3/6
Financial Health4/6
Dividends0/6

LXRX Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.

Lexicon Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lexicon Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.86
52 Week HighUS$1.03
52 Week LowUS$9.65
Beta1.46
1 Month Change42.94%
3 Month Change4.74%
1 Year Change200.00%
3 Year Change-53.63%
5 Year Change-73.91%
Change since IPO-96.30%

Recent News & Updates

Shareholder Returns

LXRXUS BiotechsUS Market
7D4.3%0.3%-0.6%
1Y200.0%25.7%33.8%

Return vs Industry: LXRX exceeded the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: LXRX exceeded the US Market which returned 33.6% over the past year.

Price Volatility

Is LXRX's price volatile compared to industry and market?
LXRX volatility
LXRX Beta1.46
Industry Beta1.03
Market Beta1

Stable Share Price: LXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LXRX's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199578Lonnel Coatshttps://www.lexpharma.com

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Valuation

Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LXRX ($4.86) is trading below our estimate of fair value ($49.58)

Significantly Below Fair Value: LXRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LXRX is good value based on its PE Ratio (18.4x) compared to the US Biotechs industry average (25.5x).

PE vs Market: LXRX is poor value based on its PE Ratio (18.4x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: LXRX is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: LXRX is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

29.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LXRX's forecast earnings growth (29.2% per year) is above the savings rate (2%).

Earnings vs Market: LXRX's earnings (29.2% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: LXRX's revenue (57.7% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: LXRX's revenue (57.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LXRX's Return on Equity is forecast to be low in 3 years time (0.5%).


Past Performance

How has Lexicon Pharmaceuticals performed over the past 5 years?

30.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LXRX has a large one-off gain of $128.1M impacting its June 30 2021 financial results.

Growing Profit Margin: LXRX's current net profit margins are higher than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: LXRX has become profitable over the past 5 years, growing earnings by 30.4% per year.

Accelerating Growth: LXRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: LXRX had negative earnings growth (-3%) over the past year, making it difficult to compare to the Biotechs industry average (4.9%).


Return on Equity

High ROE: LXRX's Return on Equity (27.8%) is considered high.


Financial Health

How is Lexicon Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LXRX's short term assets ($123.3M) exceed its short term liabilities ($32.8M).

Long Term Liabilities: LXRX's short term assets ($123.3M) exceed its long term liabilities ($1.6M).


Debt to Equity History and Analysis

Debt Level: LXRX's debt to equity ratio (8.5%) is considered satisfactory.

Reducing Debt: LXRX's debt to equity ratio has reduced from 47.1% to 8.5% over the past 5 years.

Debt Coverage: LXRX's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if LXRX's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.6yrs

Average management tenure


CEO

Lonnel Coats (56 yo)

7.17yrs

Tenure

US$3,860,671

Compensation

Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei...


CEO Compensation Analysis

Compensation vs Market: Lonnel's total compensation ($USD3.86M) is above average for companies of similar size in the US market ($USD2.33M).

Compensation vs Earnings: Lonnel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LXRX's management team is seasoned and experienced (12.6 years average tenure).


Board Members

Experienced Board: LXRX's board of directors are seasoned and experienced ( 14.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.9%.


Top Shareholders

Company Information

Lexicon Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lexicon Pharmaceuticals, Inc.
  • Ticker: LXRX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$702.146m
  • Shares outstanding: 144.47m
  • Website: https://www.lexpharma.com

Number of Employees


Location

  • Lexicon Pharmaceuticals, Inc.
  • 8800 Technology Forest Place
  • The Woodlands
  • Texas
  • 77381-1160
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 00:46
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.